Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis

Ayman Al-Shurbaji, Jon Skorve, Rolf K. Berge, Mats Rudling, Ingemar Björkhem, Lars Berglund

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effect of the sulfur-substituted fatty acid analogue 1,10 bis(carboxymethylthio)decane, also known as 3-thiadicarboxylic acid, on puromycin aminonucleoside-induced nephrotic hyperlipidemia was studied in rats. Treatment with 3-thiadicarboxylic acid (250 mg/kg) for 5 days reduced plasma levels of triglycerides from 5.8 to 2.7 mmol/L and cholesterol from 11.0 to 7.7 mmol/L. This was accounted for by decreases in very-low-density lipoprotein triglycerides, very-low-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, without any major changes in the composition of plasma lipoproteins. The activities of two enzymes involved in fatty acid synthesis (ATP:citrate lyase and fatty acid synthetase) were inhibited by 3-thiadicarboxylic acid treatment, whereas acetyl-coenzyme A carboxylase activity was unchanged. In contrast, treatment with the sulfur-substituted fatty acid analogue induced the peroxisomal β-oxidation of fatty acids ninefold and the mitochondrial β-oxidation by 54% to 73%, depending on the substrate used. This was accompanied by a 26% reduction in hepatic triglyceride secretion rate. The hepatic phosphatidate phosphohydrolase activity was unchanged. 3-Thiadicarboxylic acid treatment suppressed the activity of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, by 58%, whereas hepatic LDL receptor expression was unaltered. The activities of lipoprotein lipase and hepatic lipase were unchanged by treatment. These results demonstrated that treatment with 3-thiadicarboxylic acid ameliorates hyperlipidemia in experimental nephrosis primarily by decreasing the overproduction of very-low-density lipoprotein present. The data also indicate that hepatic very-low-density lipoprotein synthesis and secretion is strongly influenced by the availability of the fatty acid substrate under the same hyperlipidemic conditions.

Original languageEnglish (US)
Pages (from-to)1580-1586
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume13
Issue number11
StatePublished - 1993
Externally publishedYes

Fingerprint

Nephrosis
Lipid Metabolism
Fatty Acids
Liver
VLDL Lipoproteins
Hyperlipidemias
Sulfur
Triglycerides
ATP Citrate (pro-S)-Lyase
Phosphatidate Phosphatase
Cholesterol
Puromycin Aminonucleoside
Acetyl-CoA Carboxylase
VLDL Cholesterol
Fatty Acid Synthases
Lipoprotein Lipase
LDL Receptors
Enzymes
Lipase
LDL Cholesterol

Keywords

  • β-oxidation
  • 3-hydroxy-3-methylglutaryl-coenzyme A reductase
  • Cholesterol
  • Hypolipidemic drugs
  • Lipoprotein synthesis
  • Triacylglycerol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Al-Shurbaji, A., Skorve, J., Berge, R. K., Rudling, M., Björkhem, I., & Berglund, L. (1993). Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 13(11), 1580-1586.

Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis. / Al-Shurbaji, Ayman; Skorve, Jon; Berge, Rolf K.; Rudling, Mats; Björkhem, Ingemar; Berglund, Lars.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 13, No. 11, 1993, p. 1580-1586.

Research output: Contribution to journalArticle

Al-Shurbaji, A, Skorve, J, Berge, RK, Rudling, M, Björkhem, I & Berglund, L 1993, 'Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 13, no. 11, pp. 1580-1586.
Al-Shurbaji, Ayman ; Skorve, Jon ; Berge, Rolf K. ; Rudling, Mats ; Björkhem, Ingemar ; Berglund, Lars. / Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 1993 ; Vol. 13, No. 11. pp. 1580-1586.
@article{061fd1cbfbf94ad086d1b9c4e59c3a83,
title = "Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis",
abstract = "The effect of the sulfur-substituted fatty acid analogue 1,10 bis(carboxymethylthio)decane, also known as 3-thiadicarboxylic acid, on puromycin aminonucleoside-induced nephrotic hyperlipidemia was studied in rats. Treatment with 3-thiadicarboxylic acid (250 mg/kg) for 5 days reduced plasma levels of triglycerides from 5.8 to 2.7 mmol/L and cholesterol from 11.0 to 7.7 mmol/L. This was accounted for by decreases in very-low-density lipoprotein triglycerides, very-low-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, without any major changes in the composition of plasma lipoproteins. The activities of two enzymes involved in fatty acid synthesis (ATP:citrate lyase and fatty acid synthetase) were inhibited by 3-thiadicarboxylic acid treatment, whereas acetyl-coenzyme A carboxylase activity was unchanged. In contrast, treatment with the sulfur-substituted fatty acid analogue induced the peroxisomal β-oxidation of fatty acids ninefold and the mitochondrial β-oxidation by 54{\%} to 73{\%}, depending on the substrate used. This was accompanied by a 26{\%} reduction in hepatic triglyceride secretion rate. The hepatic phosphatidate phosphohydrolase activity was unchanged. 3-Thiadicarboxylic acid treatment suppressed the activity of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, by 58{\%}, whereas hepatic LDL receptor expression was unaltered. The activities of lipoprotein lipase and hepatic lipase were unchanged by treatment. These results demonstrated that treatment with 3-thiadicarboxylic acid ameliorates hyperlipidemia in experimental nephrosis primarily by decreasing the overproduction of very-low-density lipoprotein present. The data also indicate that hepatic very-low-density lipoprotein synthesis and secretion is strongly influenced by the availability of the fatty acid substrate under the same hyperlipidemic conditions.",
keywords = "β-oxidation, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Cholesterol, Hypolipidemic drugs, Lipoprotein synthesis, Triacylglycerol",
author = "Ayman Al-Shurbaji and Jon Skorve and Berge, {Rolf K.} and Mats Rudling and Ingemar Bj{\"o}rkhem and Lars Berglund",
year = "1993",
language = "English (US)",
volume = "13",
pages = "1580--1586",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis

AU - Al-Shurbaji, Ayman

AU - Skorve, Jon

AU - Berge, Rolf K.

AU - Rudling, Mats

AU - Björkhem, Ingemar

AU - Berglund, Lars

PY - 1993

Y1 - 1993

N2 - The effect of the sulfur-substituted fatty acid analogue 1,10 bis(carboxymethylthio)decane, also known as 3-thiadicarboxylic acid, on puromycin aminonucleoside-induced nephrotic hyperlipidemia was studied in rats. Treatment with 3-thiadicarboxylic acid (250 mg/kg) for 5 days reduced plasma levels of triglycerides from 5.8 to 2.7 mmol/L and cholesterol from 11.0 to 7.7 mmol/L. This was accounted for by decreases in very-low-density lipoprotein triglycerides, very-low-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, without any major changes in the composition of plasma lipoproteins. The activities of two enzymes involved in fatty acid synthesis (ATP:citrate lyase and fatty acid synthetase) were inhibited by 3-thiadicarboxylic acid treatment, whereas acetyl-coenzyme A carboxylase activity was unchanged. In contrast, treatment with the sulfur-substituted fatty acid analogue induced the peroxisomal β-oxidation of fatty acids ninefold and the mitochondrial β-oxidation by 54% to 73%, depending on the substrate used. This was accompanied by a 26% reduction in hepatic triglyceride secretion rate. The hepatic phosphatidate phosphohydrolase activity was unchanged. 3-Thiadicarboxylic acid treatment suppressed the activity of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, by 58%, whereas hepatic LDL receptor expression was unaltered. The activities of lipoprotein lipase and hepatic lipase were unchanged by treatment. These results demonstrated that treatment with 3-thiadicarboxylic acid ameliorates hyperlipidemia in experimental nephrosis primarily by decreasing the overproduction of very-low-density lipoprotein present. The data also indicate that hepatic very-low-density lipoprotein synthesis and secretion is strongly influenced by the availability of the fatty acid substrate under the same hyperlipidemic conditions.

AB - The effect of the sulfur-substituted fatty acid analogue 1,10 bis(carboxymethylthio)decane, also known as 3-thiadicarboxylic acid, on puromycin aminonucleoside-induced nephrotic hyperlipidemia was studied in rats. Treatment with 3-thiadicarboxylic acid (250 mg/kg) for 5 days reduced plasma levels of triglycerides from 5.8 to 2.7 mmol/L and cholesterol from 11.0 to 7.7 mmol/L. This was accounted for by decreases in very-low-density lipoprotein triglycerides, very-low-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, without any major changes in the composition of plasma lipoproteins. The activities of two enzymes involved in fatty acid synthesis (ATP:citrate lyase and fatty acid synthetase) were inhibited by 3-thiadicarboxylic acid treatment, whereas acetyl-coenzyme A carboxylase activity was unchanged. In contrast, treatment with the sulfur-substituted fatty acid analogue induced the peroxisomal β-oxidation of fatty acids ninefold and the mitochondrial β-oxidation by 54% to 73%, depending on the substrate used. This was accompanied by a 26% reduction in hepatic triglyceride secretion rate. The hepatic phosphatidate phosphohydrolase activity was unchanged. 3-Thiadicarboxylic acid treatment suppressed the activity of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, by 58%, whereas hepatic LDL receptor expression was unaltered. The activities of lipoprotein lipase and hepatic lipase were unchanged by treatment. These results demonstrated that treatment with 3-thiadicarboxylic acid ameliorates hyperlipidemia in experimental nephrosis primarily by decreasing the overproduction of very-low-density lipoprotein present. The data also indicate that hepatic very-low-density lipoprotein synthesis and secretion is strongly influenced by the availability of the fatty acid substrate under the same hyperlipidemic conditions.

KW - β-oxidation

KW - 3-hydroxy-3-methylglutaryl-coenzyme A reductase

KW - Cholesterol

KW - Hypolipidemic drugs

KW - Lipoprotein synthesis

KW - Triacylglycerol

UR - http://www.scopus.com/inward/record.url?scp=0027519512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027519512&partnerID=8YFLogxK

M3 - Article

C2 - 8218098

AN - SCOPUS:0027519512

VL - 13

SP - 1580

EP - 1586

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 11

ER -